BR112014019052A8 - Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer - Google Patents
Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncerInfo
- Publication number
- BR112014019052A8 BR112014019052A8 BR112014019052A BR112014019052A BR112014019052A8 BR 112014019052 A8 BR112014019052 A8 BR 112014019052A8 BR 112014019052 A BR112014019052 A BR 112014019052A BR 112014019052 A BR112014019052 A BR 112014019052A BR 112014019052 A8 BR112014019052 A8 BR 112014019052A8
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- cancer
- cdk8
- antimetastatic
- cdki
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4739—Cyclin; Prad 1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Abstract
INIBIDORES SELETIVOS DE CDK8/CDK19, SEU USO, FORMULAÇÃO FARMACÊUTICA, MÉTODOS ANTIMETASTÁTICOS E QUIMIOPREVENTIVOS PARA O CÂNCER. A presente invenção refere-se a compostos e métodos para inibição da via de Inibidor de Quinase Dependente de Ciclina (CDKI). Mais particularmente, a invenção refere-se a compostos e métodos para inibição da via de CDKI para estudos e intervenção em doenças relacionadas à senescência ou outras relacionadas à CDKI. A invenção proporciona novos compostos que têm solubilidade e/ou potência aprimorada e métodos para seu uso. Em vários aspectos, a invenção refere-se ao tratamento de câncer. A invenção fornece métodos para quimioprevenção e prevenção de recorrência de tumores ou metástases. A invenção proporciona ainda técnicas diagnósticas para o tratamento de determinados tipos de câncer. A presente invenção usa inibidores específicos de CDK8/19 e/ou medição do nível de CDK8 em um paciente.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261594023P | 2012-02-02 | 2012-02-02 | |
US201261673419P | 2012-07-19 | 2012-07-19 | |
PCT/US2013/024515 WO2013116786A1 (en) | 2012-02-02 | 2013-02-01 | Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014019052A2 BR112014019052A2 (pt) | 2017-06-20 |
BR112014019052A8 true BR112014019052A8 (pt) | 2017-07-11 |
Family
ID=47716178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014019052A BR112014019052A8 (pt) | 2012-02-02 | 2013-02-01 | Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer |
Country Status (16)
Country | Link |
---|---|
US (2) | US9321737B2 (pt) |
EP (2) | EP2809324B1 (pt) |
JP (1) | JP6193268B2 (pt) |
KR (1) | KR20150023223A (pt) |
CN (1) | CN104363913B (pt) |
AU (1) | AU2013214783B2 (pt) |
BR (1) | BR112014019052A8 (pt) |
CL (1) | CL2014002062A1 (pt) |
CO (1) | CO7151516A2 (pt) |
EA (2) | EA028595B1 (pt) |
GE (1) | GEP201706688B (pt) |
MY (1) | MY165446A (pt) |
PH (1) | PH12014501862A1 (pt) |
SG (1) | SG11201404596UA (pt) |
UA (1) | UA117342C2 (pt) |
WO (1) | WO2013116786A1 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014018891A1 (en) * | 2012-07-27 | 2014-01-30 | Biogen Idec Ma Inc. | Compounds that are s1p modulating agents and/or atx modulating agents |
KR20150044952A (ko) * | 2012-08-23 | 2015-04-27 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 신규한 페닐-피리딘/피라진 아미드 |
EP2914266B1 (en) | 2012-11-01 | 2019-06-19 | University of South Carolina | Cdk8/cdk19 selective inhibitors for use in a method for treating prostate cancer |
WO2014134169A1 (en) * | 2013-02-26 | 2014-09-04 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
WO2015100420A1 (en) | 2013-12-24 | 2015-07-02 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
EP3205645B1 (en) * | 2014-04-18 | 2019-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
AU2015296968A1 (en) * | 2014-06-10 | 2017-02-02 | University Of South Carolina | Methods and compositions for treatment of HER-positive cancers |
US20210322651A1 (en) | 2014-12-18 | 2021-10-21 | Senex Biotechnology, Inc. | Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors |
EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
KR20180003597A (ko) * | 2015-05-08 | 2018-01-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 코르티스타틴 유도체로의 치료를 위한 환자의 표적화된 선택 |
EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
KR20180073600A (ko) * | 2015-11-03 | 2018-07-02 | 루 라이센스 에이비 | 과증식성 장애의 치료를 위한 화합물 |
WO2017091836A1 (en) * | 2015-11-25 | 2017-06-01 | University Of South Carolina | Enhancement of cytarabine activity by inhibiting cdk8/19 |
JP7198489B2 (ja) * | 2016-03-23 | 2023-01-04 | 国立大学法人 岡山大学 | リン酸化sarm1、抗体、sarm1リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、sarm1改変体及び使用 |
US11285144B2 (en) | 2016-08-03 | 2022-03-29 | The Broad Institute, Inc. | Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity |
JP7142846B2 (ja) | 2017-01-30 | 2022-09-28 | 国立大学法人京都大学 | 新規化合物及び制御性t細胞の製造方法 |
WO2018151633A1 (ru) * | 2017-02-20 | 2018-08-23 | Закрытое Акционерное Общество "Биокад" | Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов |
US20220040179A1 (en) * | 2017-02-23 | 2022-02-10 | University Of South Carolina | Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis |
WO2018159805A1 (ja) | 2017-03-03 | 2018-09-07 | 国立大学法人京都大学 | 膵前駆細胞の製造方法 |
JP7152784B2 (ja) * | 2017-04-03 | 2022-10-13 | 京都薬品工業株式会社 | 新規サイクリン依存性キナーゼ8及び/又は19阻害剤 |
RU2641001C1 (ru) * | 2017-04-03 | 2018-01-15 | Закрытое Акционерное Общество "Биокад" | Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция |
AU2018333072B2 (en) * | 2017-09-18 | 2022-09-29 | Cz Biohub Sf, Llc | Methods for treating triple-negative breast cancer |
US11261184B2 (en) | 2017-10-02 | 2022-03-01 | Boehringer Ingelheim International Gmbh | [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors |
RU2763347C2 (ru) * | 2018-03-01 | 2021-12-28 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
US11014906B2 (en) | 2018-08-21 | 2021-05-25 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
EP3917523B1 (en) | 2019-02-01 | 2024-09-11 | University of South Carolina | Bicyclic pyridine compounds for use in treating cancer |
EP4249587A1 (en) | 2020-11-20 | 2023-09-27 | Orizuru Therapeutics, Inc. | Maturation agent |
CN116829697A (zh) | 2021-02-09 | 2023-09-29 | 千纸鹤治疗公司 | 促熟剂 |
EP4313050A1 (en) * | 2021-03-25 | 2024-02-07 | University of South Carolina | Cdk8/19 inhibitors for the treatment of cytokine storm |
TW202330910A (zh) | 2021-09-27 | 2023-08-01 | 國立大學法人京都大學 | T細胞的製造方法 |
KR20240130083A (ko) | 2021-11-24 | 2024-08-28 | 레그셀 가부시키가이샤 | T세포 관련 질환을 치료 또는 예방하기 위한 의약 조성물 |
KR20240116751A (ko) | 2021-11-24 | 2024-07-30 | 레그셀 가부시키가이샤 | 사람 유도성 제어성 t세포 및 그 제작 방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046206A (en) | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
ES2256968T3 (es) * | 1997-10-27 | 2006-07-16 | Agouron Pharmaceuticals, Inc. | Derivados de 4-aminotiazol, su preparacion y su uso como inhibidores de quinasas dependientes de ciclina. |
US6440959B1 (en) * | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
US20040180844A1 (en) | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
US20040180848A1 (en) | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
MXPA05010824A (es) * | 2003-04-10 | 2005-12-05 | Pfizer | Compuestos biciclicos como antagonistas del receptor nr2b. |
JP2010505386A (ja) * | 2006-05-15 | 2010-02-25 | セネックス バイオテクノロジー,インク. | Cdki経路阻害剤の同定 |
US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
-
2013
- 2013-02-01 EA EA201491399A patent/EA028595B1/ru not_active IP Right Cessation
- 2013-02-01 EP EP13704538.1A patent/EP2809324B1/en not_active Not-in-force
- 2013-02-01 SG SG11201404596UA patent/SG11201404596UA/en unknown
- 2013-02-01 EP EP18186536.1A patent/EP3431087A1/en not_active Withdrawn
- 2013-02-01 JP JP2014555805A patent/JP6193268B2/ja not_active Expired - Fee Related
- 2013-02-01 AU AU2013214783A patent/AU2013214783B2/en not_active Ceased
- 2013-02-01 MY MYPI2014002269A patent/MY165446A/en unknown
- 2013-02-01 UA UAA201409643A patent/UA117342C2/uk unknown
- 2013-02-01 WO PCT/US2013/024515 patent/WO2013116786A1/en active Application Filing
- 2013-02-01 BR BR112014019052A patent/BR112014019052A8/pt not_active Application Discontinuation
- 2013-02-01 GE GEAP201313566A patent/GEP201706688B/en unknown
- 2013-02-01 EA EA201791284A patent/EA032429B1/ru not_active IP Right Cessation
- 2013-02-01 KR KR1020147024672A patent/KR20150023223A/ko not_active Application Discontinuation
- 2013-02-01 US US13/757,682 patent/US9321737B2/en active Active
- 2013-02-01 CN CN201380017703.9A patent/CN104363913B/zh not_active Expired - Fee Related
-
2014
- 2014-08-01 CL CL2014002062A patent/CL2014002062A1/es unknown
- 2014-08-18 PH PH12014501862A patent/PH12014501862A1/en unknown
- 2014-08-30 CO CO14191136A patent/CO7151516A2/es unknown
-
2016
- 2016-03-09 US US15/065,083 patent/US10993945B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2809324B1 (en) | 2018-08-01 |
US10993945B2 (en) | 2021-05-04 |
JP6193268B2 (ja) | 2017-09-06 |
PH12014501862A1 (en) | 2014-11-24 |
EA032429B1 (ru) | 2019-05-31 |
CN104363913A (zh) | 2015-02-18 |
UA117342C2 (uk) | 2018-07-25 |
CN104363913B (zh) | 2018-08-21 |
US9321737B2 (en) | 2016-04-26 |
GEP201706688B (en) | 2017-06-26 |
SG11201404596UA (en) | 2014-10-30 |
CO7151516A2 (es) | 2014-12-29 |
US20170071942A1 (en) | 2017-03-16 |
US20140038958A1 (en) | 2014-02-06 |
AU2013214783B2 (en) | 2017-07-06 |
AU2013214783A1 (en) | 2014-08-28 |
KR20150023223A (ko) | 2015-03-05 |
CL2014002062A1 (es) | 2015-03-20 |
EP2809324A1 (en) | 2014-12-10 |
EA028595B1 (ru) | 2017-12-29 |
MY165446A (en) | 2018-03-22 |
WO2013116786A1 (en) | 2013-08-08 |
JP2015506376A (ja) | 2015-03-02 |
BR112014019052A2 (pt) | 2017-06-20 |
EA201491399A1 (ru) | 2015-04-30 |
EP3431087A1 (en) | 2019-01-23 |
EA201791284A1 (ru) | 2017-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014019052A8 (pt) | Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer | |
BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
BR112016002465A2 (pt) | terapia da combinação para o tratamento de câncer | |
BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
BR112015027951A8 (pt) | arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit | |
BR112016012713A2 (pt) | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
EA201591371A1 (ru) | Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock | |
DOP2014000059A (es) | Derivados de estra1,3,5(10),16tetraen3carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
ECSP15000868A (es) | Derivados de estra1,3,5(10),16tetraeno 3sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
BR112015027440A2 (pt) | DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO | |
PH12016502353A1 (en) | Pharmaceutical composition | |
BR112016024421A2 (pt) | composição farmacêutica, cápsula e uso da composição farmacêutica | |
BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
MX2015012526A (es) | Inhibodores macrociclicos de cinasa rip2. | |
MX2015011359A (es) | Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2). | |
MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
BR112022024700A2 (pt) | Inibidores de atr e usos dos mesmos | |
MY186523A (en) | Macrocyclic rip2 kinase inhibitors | |
BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase | |
BR112019008516A2 (pt) | derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo | |
BR112015005392A2 (pt) | formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |